Preferred Label : Anti-CD33/CD3 Bispecific Antibody JNJ-67571244;
NCIt definition : A bispecific antibody possessing two antigen-recognition and binding sites, one for
the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell
receptor (TCR), and one for the tumor-associated antigen (TAA) CD33, with potential
immunostimulating and antineoplastic activities. Upon intravenous administration,
anti-CD33/CD3 bispecific antibody JNJ-67571244 binds to both the CD3 antigen on cytotoxic
T-lymphocytes (CTLs) and the CD33 antigen expressed on certain tumor cells, thereby
crosslinking tumor cells and CTLs. This activates and redirects CTLs to CD33-expressing
tumor cells, which results in CTL-mediated killing of CD33-expressing tumor cells.
CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic
stem and progenitor cells (HSPCs) and is overexpressed on a variety of cancer cell
types, including acute myeloid leukemia (AML). It plays a key role in tumor initiation,
proliferation and progression.;
Molecule name : JNJ-67571244; JNJ 67571244;
NCI Metathesaurus CUI : CL970869;
Origin ID : C162296;
UMLS CUI : C5206502;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
